Document:

Document

    

Exhibit 10.1

CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
AMENDMENT NO.1 TO CONSULTING AGREEMENT
This Amendment No.1 (this “Amendment”) to the Consulting Agreement (the “Consulting Agreement”) dated May 18, 2020, effective as of May 11, 2020, by and between Myovant Sciences GmbH, having a registered office at Viaduktstrasse 8, 4051 Basel, Switzerland (“Myovant”), and Sumitovant Biopharma, Inc., having an office at 151 W. 42nd Street, 15th Floor, New York NY 10036 (“Sumitovant” or “Consultant”), is being entered into effective as of November 11, 2020, by and between Myovant and Sumitovant.
All capitalized terms used but not otherwise defined in this Amendment have the meanings given to them in the Consulting Agreement.  The Consulting Agreement is hereby amended as follows:
1.Section 2.1 is hereby amended and restated in its entirety to the following:
Subject to the terms and provisions set forth below in this Section 2, the term of Consultant’s engagement will begin on May 11, 2020 and continue until March 31, 2021 or such earlier time when Myovant notifies Consultant that it has hired a permanent Chief Commercial Officer and the Individual Consultant has completed its transitioned all responsibilities to such permanent Chief Commercial Officer. 
2.Section 3.1 is hereby amended and restated in its entirety to the following: 
In consideration of the Services provided by Consultant, Myovant shall provide Consultant with $[***]/hour (the “Fee”).  
All other provisions of the Consulting Agreement shall continue in full force and effect.  The provisions of 5-17 of the Consulting Agreement shall apply to this Amendment as if included in this Amendment.
[Remainder of this page intentionally left blank]

									
	CONFIDENTIAL	Page 1 of 2
	

    

IN WITNESS WHEREOF, the duly authorized representatives of the parties hereto have caused this Agreement to be duly executed as of the date set forth.

															
	Myovant Sciences GmbH (“Myovant”)    
		Sumitovant Biopharma, Inc. “Consultant”)

	By:	/s/ Elke Hunsche		By:	/s/ Tara Soni
	Name:	Elke Hunsche		Name	Tara Soni
	Title	VP, Global Market Access & HEOR		Title	Head of Legal
	Date:	11/9/2020		Date:	11/6/2020

									
	CONFIDENTIAL	Page 2 of 2Document

Exhibit 10.2

CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

Amendment No. 2 to License Agreement
This Amendment No. 2 (this "Amendment") to the License Agreement, dated April 29, 2016, as previously amended effective November 19, 2019 (the “License Agreement”) by and between Takeda Pharmaceuticals International AG, a company incorporated wider the laws of Switzerland having its principal place of business at Thurgauerstrasse 130, 8152 Glattpark-Opfikon Zurich, Switzerland (“Takeda” or “TPI”) and Myovant Sciences Ltd. (formally with the name "Roivant Endocrinology Ltd."), an exempted limited company incorporated under the laws of Bermuda, and having its Granted office at 2 Church Street, Hamilton, Bermuda (the “Former Licensee”) is being entered into as of December 15, 2020 (the “Amendment Effective Date”), by and between Takeda and Myovant Sciences GmbH, a Switzerland limited liability company with an address of Viaduktstrasse 8, 4051 Basel, Switzerland (the “Licensee”) in accordance with Section 16.12 of the License Agreement.
For clarification purpose, the Former Licensee assigned all of its rights and obligations under the License Agreement to the Licensee pursuant to that certain Asset and Contribution Agreement, dated as of November 11, 2016, by and between the Former Licensee and the Licensee, in accordance with Section 16.3 of the License Agreement.
All capitalized terms used but not otherwise defined in this Amendment have the meanings given to them in the License Agreement.  
Takeda and Licensee wish to further amend the License Agreement to, among other things, reflect ownership by an Affiliate of TPI of certain intellectual property rights, which TPI sublicensed to Licensee pursuant to the License Agreement.
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the License Agreement is hereby amended as follows:
1.Schedule 1.151 of the License Agreement is hereby deleted and replaced in its entirety with the Schedule 1.151 attached hereto as Exhibit A, which includes only Patents that are solely owned by Takeda or one of its Affiliates.
2.Section 1.71 (Joint Patent Rights) of the License Agreement is hereby deleted and replace with the following: 
“1.71  “Joint Patent Rights” means all Patent Rights Covering Joint Inventions, including those Patent Rights set forth on Schedule 1.71.”
3.A new Schedule 1.71, attached hereto as Exhibit B, is hereby added to the License Agreement.
4.Section 11.2.2 is hereby deleted and replaced with the following:
“Takeda or one of its Affiliates is the sole and exclusive owner of the entire right, title, and interest in the Takeda Patent Rights set forth on Schedule 1.151 (Takeda Patent Rights) free of any encumbrance, lien, or claim of ownership by any Third Party.”
Amendment No. 2 to License Agreement

CONFIDENTIAL

5.Section 11.2.11(b) is hereby deleted and replaced with the following:
“Ownership of Takeda Patent Rights. Except for the obligations under the [***], Takeda or one of its Affiliates is the sole and exclusive owner of the entire right, title, and interest in the Added Patents set forth on Schedule 1.151 free of any encumbrance, lien, or claim of ownership by any Third Party.”
6.Section 11.2 of the License Agreement is amended to add the following:
11.2.12    Takeda In-License. With respect to that certain License Agreement (Non-Core Pipeline Assets) between Takeda Pharmaceutical Company Ltd. (“TPC”) and Takeda effective February 1, 2016 as amended (the “TPC-TPI Exclusive License Agreement”) Takeda hereby represents and warrants that:
(a)Disclosure. Takeda has disclosed to Licensee a full and complete copy of the TPC-TPI Exclusive License Agreement, including any and all amendments or supplements thereto that are material to Licensee’s rights under this Agreement, subject only to redactions with respect to terms and conditions that are not material to Licensee’s rights under this Agreement.
(b)Effectiveness. The TPC-TPI Exclusive License Agreement is in full force and effect according to its terms and neither Takeda nor TPC is in material breach thereof.  
7.Section 11.3 of the License Agreement is amended to add the following:
11.3.5    Takeda In-License. With respect to the TPC-TPI Exclusive License Agreement (defined in Section 11.2.12), and only with respect to any right sublicensed or otherwise conveyed to Licensee under this Agreement, including rights related to the prosecution, maintenance, enforcement or defense of any Takeda Technology, Takeda hereby covenants that it shall not (a) terminate the TPC-TPI Exclusive License Agreement, (b) act, or fail to act, in any manner that would cause TPC to have the right to terminate the TPC-TPI Exclusive License Agreement, or (c) assign or otherwise transfer ownership of its rights under the TPC-TPI Exclusive License Agreement except in conjunction with the concurrent assignment to the same entity of all of Takeda’s rights and obligations this Agreement in accordance with Section 16.3 (Assignment).  Nothing in this Section 11.3.5 shall be construed to waive or release any rights or obligations that either Party may have under any other provision of this Agreement.
8.All other provisions of the License Agreement shall continue in full force and effect. The provisions in Article 16 (Miscellaneous) of the License Agreement shall apply to this Amendment as if included in this Amendment.
[Remainder of this page intentionally left blank]

Amendment No. 2 to License Agreement

CONFIDENTIAL

IN WITNESS WHEREOF, each of Takeda Pharmaceuticals International AG and Myovant Sciences GmbH have caused this Amendment to be executed by their respective duly authorized officers as of the date first above written, each copy of which will for all purposes be deemed to be an original.

															
		TAKEDA PHARMACEUTICAL INTERNATIONAL AG

			MYOVANT SCIENCES GMBH
	By:			By:	/s/ Dr. Slava Rakov
	Name:			Name:	Dr. Slava Rakov
	Title:			Title:	Director and VP Medical Affairs
	Date:			Date:	14/24/2020
					
	By:				
	Name:				
	Title:				
	Date:				

Amendment No. 2 to License Agreement

CONFIDENTIAL

IN WITNESS WHEREOF, each of Takeda Pharmaceuticals International AG and Myovant Sciences GmbH have caused this Amendment to be executed by their respective duly authorized officers as of the date first above written, each copy of which will for all purposes be deemed to be an original.

															
		TAKEDA PHARMACEUTICAL INTERNATIONAL AG

			MYOVANT SCIENCES GMBH
	By:	/s/ Charles Alexander		By:	
	Name:	Charles Alexander		Name:	
	Title:	Head International BD		Title:	
	Date:	16/12/2020		Date:	
					
	By:	/s/ Antonio Raffaele Toma			
	Name:	Antonio Raffaele Toma			
	Title:	Authorized signatory			
	Date:	16 December 2020			

						
		

Amendment No. 2 to License AgreementDocument

Exhibit 10.3

						
	
	Sumitomo Dainippon Pharma Co., Ltd. 
3-1, Kyobashi 1-chome, Chuo-ku, 
Tokyo 104-8356, Japan

December 22, 2020

Myovant Sciences Ltd.
Suite 1, 3rd Floor, 11-12 St. James’s Square,
London, SW1Y 4LB, United Kingdom
c/o Myovant Sciences, Inc.
2000 Sierra Point Parkway, 9th Floor
Brisbane, CA 94005, the United States of America

Re:  $200,000,000 Credit Facility

Ladies and Gentlemen:
Reference is made to the commitment letter dated as of August 5, 2020 (the “Commitment Letter”), from Sumitomo Dainippon Pharma Co., Ltd., a company (Kabushiki Kaisha) incorporated under the laws of Japan (the “Lender”), to Myovant Sciences Ltd., an exempted company organized under the laws of Bermuda (the “Borrower”), with respect to a proposed $200,000,000 credit facility (the “Credit Facility”), the Summary of Principal Terms and Conditions attached thereto (the “Summary of Terms”), and the letter dated as of September 29, 2020, from the Lender to the Borrower, with respect to the extension of the expiration date in the Commitment Letter.  
The Lender’s undertaking and commitment under the Commitment Letter expires on December 31, 2020, unless definitive documentation of the Credit Facility is executed and delivered prior to such date.  The Lender hereby extends the December 31, 2020, expiration date in the Commitment Letter to March 31, 2021.
The Borrower reaffirms its agreements set forth in the Commitment Letter.  Except as specifically provided herein, all terms and conditions of the Commitment Letter and the Summary of Terms remain in full force and effect, without waiver or modification.  

									
		Very truly yours,
		SUMITOMO DAINIPPON PHARMA CO., LTD.
		By:	/s/ Shigeyuki Nishinaka
		Name:	Shigeyuki Nishinaka
		Title:
	Senior Executive Officer

ACCEPTED AND AGREED TO
AS OF THE DATE FIRST ABOVE WRITTEN:

						
	MYOVANT SCIENCES LTD.

	By:	/s/ Marianne Romeo

	Name:	Marianne Romeo

	Title:	Head, Global Transactions & Risk Management

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]